Validation of a flow cytometry based G2M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition

Journal of Immunological Methods

Volumn 363, Issue 2, 2011, Pages 135-142

  Estevam, Jose ^a   Danaee, Hadi ^a   Liu, Ray ^a   Ecsedy, Jeffrey ^a   Trepicchio, William L ^a   Wyant, Timothy ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Aurora A; Cell cycle; Flow cytometry; Pharmacodynamic; Phytohemagglutinin; Validation

Indexed keywords

AURORA A KINASE; AURORA KINASE INHIBITOR; MLN 8237; UNCLASSIFIED DRUG;

ARTICLE; BIOSTATISTICS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; DRUG BLOOD LEVEL; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; SIMULATION; VALIDATION STUDY;

ANTHRAQUINONES; AZEPINES; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; G2 PHASE; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; REPRODUCIBILITY OF RESULTS;

EID: 78650016649     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.09.021     Document Type: Article

References (19)

1. Andrews P.D., Knatko E., Moore W.J., Swedlow J.R. Mitotic mechanics: the auroras come into view. Current Opinion in Cell Biology 2003, 15:672.
2. Bansal S., DeStefano A. Key elements of bioanalytical method validation for small molecules. The AAPS Journal 2007, 9(1):E109.
3. Carvajal R.D., Tse A., Schwartz G.K. Aurora kinases: new targets for cancer therapy. Clinical Cancer Research 2006, 12:6869.
4. Dean P.N. Methods of data analysis in flow cytometry. Flow Cytometry: Instrumentation and Data Analysis, Chapter 6 1985, Academic Press, London. M.A. Van Dilla, P.N. Dean, O.D. Laerum, M.R. Melamed (Eds.).
5. DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharmaceutical Research 2003, 20(11):1885.
6. Findlay J.W.A., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. Journal of Pharmaceutical and Biomedical Analysis 2000, 21:1249.
7. Fu J., Bian M., Jiang Q., Zhang C. Roles of aurora kinases in mitosis and tumorigenesis. Molecular Cancer Research 2007, 5(1):1.
8. Gautschi O., Heighway J., Mack P.C., Purnell P.R., Lara P.N., Gandara D.R. Aurora kinases as anticancer drug targets. Clinical Cancer Research 2008, 14(6):1639.
9. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., Richards S.M., Rup B., Shores E., Swanson S.J., Wakshull E. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. Journal of Immunological Methods 2007, 321(1-2):1.
10. Huck J.J., Zhang M., Hyer M.L., Manfredi M.G. Anti-tumor activity of the aurora a inhibitor MLN8237 in diffuse large B-cell lymphoma preclinical models [abstract 1592]. Blood 2008, 112(Suppl 16).
11. Katayama H., Brinkley W.R., Sen S. The aurora kinases: role in cell transformation and tumorigenesis. Cancer and Metastasis Reviews 2003, 22(4):451.
12. Keen N., Taylor S. Aurora-kinase inhibitors as anticancer agents. Nature Reviews. Cancer 2004, 4:927.
13. Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Greem M., Duan L., Rogers J.A., Millham R., O'Brien P.J.O., Sailstad J., Khan M., Ray C., Wagnen J.A. Fit-for-purpose method development and validation for successful biomarker measurement. Pharmaceutical Research 2006, 23(2):312.
14. Nunez R. DNA measurement and cell cycle analysis by flow cytometry. Current Issues in Molecular Biology 2001, 3(3):67.
15. Purvis N., Stelzer G. Multi-platform, multi-site instrumentation and reagent standardization. Cytometry 1998, 33(2):156.
16. Sausville E. Aurora kinases dawn as cancer drug targets. Nature Medicine 2004, 234.
17. Shapiro H.M. Practical Flow Cytometry 2003, John Wiley & Sons Inc., Hoboken, New Jersey, Chapter 10.
18. Smolec J., DeSilva B., Smith W., Weiner R., Kelly M., Lee B., Khan M., Tacey R., Hill H., Celniker A., Shah V., Bowsher R., Mire-Sluis A., Findlay J.W., Saltarelli M., Quarmby V., Lansky D., Dillard R., Ullmann M., Keller S., Karnes H.T. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharmaceutical Research 2005, 22(9):1425.
19. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharmaceutical Research 2007, 24(10):1962.